Moreover, the consequences we have shown of increased Scn1a expression point to the need for quantitative precision in genetic therapies intended to increase SCN1A transcription [10] for treatment of seizures in Dravet syndrome associated with SCN1A haploinsufficiency. The gene discussed is SCN1A; the disease is encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.